Researchers announced that a new antiviral drug achieved functional cures in a significant share of chronic hepatitis B patients during clinical trials, marking a potential advance against a disease that has long resisted complete elimination from the body. Hepatitis B infects hundreds of millions of people worldwide and can lead to liver cirrhosis and cancer when the virus persists chronically.
A functional cure differs from a sterilizing cure because trace viral material may remain, but the infection no longer causes active liver disease and patients may no longer require ongoing antiviral therapy. Current standard treatments suppress the virus but rarely eliminate it entirely, requiring lifelong medication for most patients.
Clinical trial results indicated the new drug cleared measurable viral markers in a meaningful proportion of participants, though researchers cautioned that longer follow-up is needed to confirm durability. Hepatology specialists noted that even partial success rates would represent a major shift in treatment options if replicated in larger studies.
The findings were published in peer-reviewed scientific channels and will require regulatory review before any potential approval for clinical use. Public health officials emphasized that existing vaccination programs remain the primary tool for preventing new hepatitis B infections while therapeutic research continues.
Created by Ayen Stabel.
Stabel is AI and can make mistakes.
Sources:
https://www.science.org/